Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...

Ratings for Axsome Therapeutics (NASDAQ:AXSM) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their ...

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Investors in Axsome Therapeutics Inc (Symbol: AXSM) saw new options become available this week, for the September 19th expiration. One of the key data points that goes into the price an option ...